CNS (Cohen & Steers Inc.) Stock Analysis - Financials

Cohen & Steers Inc. (CNS) is a publicly traded Financial Services sector company. As of May 21, 2026, CNS trades at $71.63 with a market cap of $3.71B and a P/E ratio of 23.58. CNS moved -0.15% today. Year to date, CNS is +10.53%; over the trailing twelve months it is -11.12%. Its 52-week range spans $58.39 to $110.67. Analyst consensus is neutral with an average price target of $64.50. Rallies surfaces CNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CNS's key financials?

CNS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CNS recently traded at $71.63. Market cap is $3.71B. P/E ratio is 23.58. Revenue is $567.29M.

CNS Key Metrics

Key financial metrics for CNS
MetricValue
Price$71.63
Market Cap$3.71B
P/E Ratio23.58
EPS$3.03
Dividend Yield0.67%
52-Week High$110.67
52-Week Low$58.39
Volume213.12K
Avg Volume0
Revenue (TTM)$567.29M
Net Income$155.33M
Gross Margin0.00%

CNS Annual Financials

YearRevenueNet IncomeEPS
2025$556.12M$157.40M$2.99
2023$489.64M$136.61M$2.62
2022$566.91M$149.49M$3.51
2021$583.83M$226.15M$4.38

Latest CNS News

Recent CNS Insider Trades

  • POLI FRANCIS C sold 10.00K (~$657.30K) on Feb 12, 2026.
  • POLI FRANCIS C sold 4.70K (~$306.37K) on Feb 11, 2026.
  • POLI FRANCIS C sold 5.00K (~$330.00K) on Feb 11, 2026.

CNS Analyst Consensus

2 analysts cover CNS: 0 strong buy, 1 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $64.50.

Common questions about CNS

What are CNS's key financials?
CNS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CNS recently traded at $71.63. Market cap is $3.71B. P/E ratio is 23.58. Revenue is $567.29M.
Is CNS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CNS. It does not provide personalized investment advice.
CNS

CNS